Press release - for immediate release
31 October 2016
New Webinar on Implementing the ambr® 250 Modular Benchtop Bioreactor - With a Case Study from Cobra Biologics Detailing how the system helps Fast-track Process Development of Microbial Products
Sartorius Stedim Biotech (SSB) today announced that it is co-presenting a new bioprocess webinar with Cobra Biologics, a leading international Contract Development and Manufacturing Organization (CDMO), on Tuesday 15th November. Two live events (at 09.00 GMT and 16.00 GMT) will detail how Cobra Biologics is using the ambr® 250 modular to accelerate process development and screening of microbial products and platform processes.
During the live one-hour webinar, Dr Barney Zoro, ambr Product Manager at SSB, will provide a brief overview of the ambr® 250 modular, a new high performance benchtop bioreactor system for parallel fermentation or cell culture in 100-250mL single-use vessels.
Dr Andrew Frazer, Process Development Leader at Cobra Biologics, will describe how the ambr 250 modular system has been implemented there to fast track strain selection of microbial products.
Dr Frazer will also discuss why the single-use system delivers improvements in throughput, as well as flexibility and analysis capabilities, providing Cobra Biologics’ scientists with readily-scalable microbial processes in significantly shorter timelines than traditional benchtop bioreactor systems can.
To join the webinar and receive a recording to listen to or watch on-demand, scientists should register at using the link beneath this news release.
Dr Barney Zoro, ambr Product Manager, at SSB commented: "I am delighted that Dr Frazer will be presenting data on how Cobra Biologics is implementing the ambr 250 modular into their upstream bioprocess workflow.”
Zoro continued: “Scientists wanting rapid set-up and turnaround of strain selection and process development should register now for this interesting webinar to learn why using the new ambr technology can help to cost-effectively optimize productivity and quality of microbial biotherapeutics and vaccines.”
For further information, please contact: